trastuzumab-autophilic peptide conjugate (InNexus Biotechnology)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nametrastuzumab-autophilic peptide conjugate (InNexus Biotechnology)

Drug Alias Nameanti-HER2/neu monoclonal antibodies (InNexus)anti-HER2/neu monoclonal antibodies (InNexus)DXL-702

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesInNexus Biotechnology Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesInNexus Biotechnology Inc

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A